Monoclonal antibodies, antibody-drug conjugates (ADCs), and CAR-T-based treatments have shown that CD70 is the optimal target due to its very limited expression pattern in certain blood cancers and solid tumors. Here, CD70 is linked to hematopoietic and lymphoid system neoplasm.